This article is more than 5 years old. Information may no longer be current.

FDA approves somatropin for short stature, Prader-Willi syndrome in children

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved an expanded indication for the growth hormone injection somatropin for the treatment of idiopathic short stature and Prader-Willi syndrome in children, Novo Nordisk announced in a press release.

Somatropin (Norditropin) is also indicated to treat children with low or no GH, children with Noonan syndrome, Turner syndrome or who are born small for gestational age, and adults who do not make enough GH.

In 2015, the FDA approved the Norditropin FlexPro 30-mg prefilled pen as an additional option for patients with GH disorders. Other Norditropin products include the 5-mg, 10-mg and 15-mg prefilled pens.